| Bid | 1.31 |
| Market Cap | 52.00M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.17 |
| PE Ratio (ttm) | -1.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.5 |
| Volume | 159,657 |
| Avg. Volume (20D) | 421,949 |
| Open | 1.45 |
| Previous Close | 1.42 |
| Day's Range | 1.35 - 1.48 |
| 52-Week Range | 1.30 - 6.68 |
| Beta | undefined |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclini...
Analyst Forecast
According to 3 analyst ratings, the average rating for PDSB stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 907.19% from the latest price.
2 months ago · seekingalpha.com
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call TranscriptPDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer...
2 months ago · proactiveinvestors.co.uk
EMV Capital highlights progress update from portfolio company PDS BiotechEMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said: "Since our last ...
